Four-Drug attack on rare brain cancer shows promise in clinical trial
NCT ID NCT07350850
Summary
This study is testing whether adding two newer drugs (sintilimab and pirtobrutinib) to standard chemotherapy (methotrexate and rituximab) works better for people with newly diagnosed primary central nervous system lymphoma (PCNSL), a rare brain cancer. Researchers will compare this four-drug combination against standard treatments that doctors normally choose. The goal is to see if the new combination helps more patients achieve complete remission and live longer with manageable side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanxi Provincial People's Hospital
NOT_YET_RECRUITINGTaiyuan, Shanxi, 030012, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Fujian Medical University
RECRUITINGXiamen, Fujian, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430000, China
Conditions
Explore the condition pages connected to this study.